Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m
Adult
Appetite Depressants
/ therapeutic use
Body Mass Index
Cohort Studies
Combined Modality Therapy
Female
Gastrectomy
Humans
Hypoglycemic Agents
/ therapeutic use
Laparoscopy
Male
Middle Aged
Obesity, Morbid
/ therapy
Phentermine
/ therapeutic use
Topiramate
/ therapeutic use
Treatment Outcome
Weight Loss
Antiobesity medication
Phentermine/topiramate extended release
Sleeve gastrectomy
Super obesity
Journal
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
ISSN: 1878-7533
Titre abrégé: Surg Obes Relat Dis
Pays: United States
ID NLM: 101233161
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
21
01
2019
revised:
15
04
2019
accepted:
16
04
2019
pubmed:
31
5
2019
medline:
25
7
2020
entrez:
1
6
2019
Statut:
ppublish
Résumé
Super obesity (body mass index [BMI] ≥50 kg/m We studied whether the pre and postoperative use of phentermine and topiramate (phen/top) combined with laparoscopic sleeve gastrectomy (LSG) in super obesity increases the odds of achieving a BMI <40 at 2 years postoperatively. Academic medical center in Winston Salem, North Carolina. We recruited patients between 2014 and 2016 who had a BMI ≥50 and planned to undergo LSG (n = 25) to participate in an open-label trial. Participants took phen/top (7.5/46-15/92 mg/d) for at least 3 months preoperatively and 2 years postoperatively. We compared weight loss, BMI changes, and odds for achieving BMI <40 for phen/top + LSG to historical controls. Controls had an initial BMI ≥50 and underwent LSG, without phen/top, at our center during the same timeframe (n = 40). Of the 25 participants recruited, 13 completed LSG. Phen/top participants had a baseline BMI of 61.2 ± 7.1 kg/m Compared with LSG alone, phen/top combined with LSG may help patients with a BMI >50 achieve greater weight loss and reach a BMI <40. Long-term, controlled trials are needed to follow up these results.
Sections du résumé
BACKGROUND
BACKGROUND
Super obesity (body mass index [BMI] ≥50 kg/m
OBJECTIVES
OBJECTIVE
We studied whether the pre and postoperative use of phentermine and topiramate (phen/top) combined with laparoscopic sleeve gastrectomy (LSG) in super obesity increases the odds of achieving a BMI <40 at 2 years postoperatively.
SETTING
METHODS
Academic medical center in Winston Salem, North Carolina.
METHODS
METHODS
We recruited patients between 2014 and 2016 who had a BMI ≥50 and planned to undergo LSG (n = 25) to participate in an open-label trial. Participants took phen/top (7.5/46-15/92 mg/d) for at least 3 months preoperatively and 2 years postoperatively. We compared weight loss, BMI changes, and odds for achieving BMI <40 for phen/top + LSG to historical controls. Controls had an initial BMI ≥50 and underwent LSG, without phen/top, at our center during the same timeframe (n = 40).
RESULTS
RESULTS
Of the 25 participants recruited, 13 completed LSG. Phen/top participants had a baseline BMI of 61.2 ± 7.1 kg/m
CONCLUSIONS
CONCLUSIONS
Compared with LSG alone, phen/top combined with LSG may help patients with a BMI >50 achieve greater weight loss and reach a BMI <40. Long-term, controlled trials are needed to follow up these results.
Identifiants
pubmed: 31147285
pii: S1550-7289(19)30159-5
doi: 10.1016/j.soard.2019.04.017
pii:
doi:
Substances chimiques
Appetite Depressants
0
Hypoglycemic Agents
0
Topiramate
0H73WJJ391
Phentermine
C045TQL4WP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1039-1043Informations de copyright
Copyright © 2019 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.